Nuvectis Pharma, Inc.
Clinical trials sponsored by Nuvectis Pharma, Inc., explained in plain language.
A biopharmaceutical company developing precision medicines for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug combo aims to outsmart resistant lung cancer Results expected Dec 2026 (estimated)
- New pill shows promise against tough cancers in early trial Results expected Mar 2027 (estimated)
- Can a new drug combo outsmart resistant lung cancer? Results expected Aug 2027 (estimated)
-
Can a new drug combo outsmart resistant lung cancer?
Disease control Recruiting nowThis trial is testing whether adding an experimental drug called NXP900 to the standard treatment lorlatinib can help people with advanced ALK-positive non-small cell lung cancer. The study includes adults who have already been treated with lorlatinib and whose cancer has not bee…
Phase 1 • Sponsor: Nuvectis Pharma, Inc. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New pill shows promise against tough cancers in early trial
Disease control Recruiting nowThis study tests a new oral drug called NXP900 in people with advanced solid tumors (like lung, kidney, or mesothelioma) that have not responded to standard treatments. The trial has two parts: first, finding the right dose, and then seeing if the drug shrinks tumors. It is a fir…
Phase 1 • Sponsor: Nuvectis Pharma, Inc. • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New drug combo aims to outsmart resistant lung cancer
Disease control Recruiting nowThis early-phase trial tests a new oral drug called NXP900 combined with the standard drug osimertinib in 18 adults with advanced EGFR-mutated non-small cell lung cancer that has progressed on prior osimertinib. The main goals are to check safety and see if the combination can sh…
Phase 1 • Sponsor: Nuvectis Pharma, Inc. • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC